| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Phytic acid potassium is a potent inhibitor of beta-secretase 1 (BACE1), the enzyme that initiates the formation of beta-amyloid plaques in the brains of Alzheimer's patients. BACE1 (beta-site APP-cleaving enzyme 1) cleaves the amyloid precursor protein (APP) to generate amyloid-beta (Abeta) peptides, which aggregate into senile plaques characteristic of Alzheimer's disease. Phytic acid potassium also chelates divalent and trivalent cations, a major determinant of zinc bioavailability.
|
|---|---|
| ln Vitro |
In vitro, phytic acid dipotassium salt inhibits beta-secretase 1 (BACE1) with an IC₅0 of approximately 0.25 uM. This potent inhibition is the primary reported in vitro activity. The compound also functions as a potent chelator of divalent and trivalent cations (e.g., Ca2+, Fe3+, Zn2+) in vitro. This chelation property underlies many of its biological effects, including its impact on mineral bioavailability and potential antioxidant activity.
|
| ln Vivo |
In vivo, phytic acid (as the free acid or salt) has been studied for its effects on mineral absorption (can reduce absorption of calcium, iron, and zinc), its antioxidant properties (due to metal chelation that reduces free radical formation), and its potential anticancer effects in animal models. It also exhibits hypocalcemic and hypocalciuric effects, reducing urinary calcium excretion in rats fed high-calcium diets. Phytic acid may have beneficial effects on kidney stone formation and blood glucose modulation.
|
| Enzyme Assay |
For non-cellular assays (enzyme inhibition), BACE1 activity is measured using a fluorescence resonance energy transfer (FRET) assay. The reaction mixture (50 uL) contains 50 mM sodium acetate (pH 4.5), 1 mM FRET substrate (Rh-EVNLDAEFK-Quencher), and various concentrations of phytic acid potassium (0-5 uM). The reaction is initiated by adding recombinant human BACE1 (50 nM), incubated at 37degC for 60 minutes, and fluorescence (excitation 540 nm, emission 585 nm) is measured. IC₅0 values are calculated from dose-response curves.
|
| Cell Assay |
For cell-based assays, human neuroblastoma cells (e.g., SH-SY5Y) are cultured in DMEM with 10% FBS. Cells are seeded in 6-well plates (1×10⁶ cells/well) and treated with phytic acid potassium (0.1-100 uM) for 24-48 hours. BACE1 activity in cell lysates is measured using a similar FRET assay. Alternatively, Abeta40 and Abeta42 levels in conditioned medium are measured by ELISA. Cell viability is assessed by MTT assay. For metal chelation studies, atomic absorption spectroscopy or colorimetric assays (e.g., using Ferrozine for iron) are conducted.
|
| Animal Protocol |
For in vivo animal experiments, rodent models (rats or mice) are used. For lead poisoning studies, mice are given lead acetate in drinking water (0.5% for 8 days) to induce lead poisoning. Calcium phytate (the calcium salt, 20 g/kg) is mixed into the feed for 8 days. Blood and tissue lead levels are measured by atomic absorption spectrophotometry. For mineral absorption studies, rats are fed high-calcium diets with or without calcium phytate for 6 days. Urine and feces are collected, and calcium excretion is measured by atomic absorption. For Alzheimer's research, transgenic APP/PS1 mice are administered phytic acid potassium in drinking water or by oral gavage (50-200 mg/kg/day) for 8-12 weeks, followed by assessment of Abeta plaque burden by immunohistochemistry and behavioral tests (Morris water maze).
|
| ADME/Pharmacokinetics |
Phytic acid potassium is an endogenous metabolite with a molecular weight of approximately 736.49 (for dipotassium salt). The compound is highly water-soluble (100 mg/mL) due to its multiple phosphate groups. It is a potent chelator of divalent and trivalent cations. At physiological pH, it carries a high negative charge. In vivo, phytic acid is not significantly metabolized by humans; it is either absorbed intact or passes through the gastrointestinal tract. It can be stored at -20degC in sealed containers.
|
| Toxicity/Toxicokinetics |
Phytic acid potassium has low acute toxicity. The oral LD₅0 in rats is >2,000 mg/kg. However, as a dietary phytate, high intake can reduce the bioavailability of essential minerals (iron, zinc, calcium), potentially leading to deficiencies over long periods. No significant acute adverse effects are observed at typical research doses. Standard handling precautions should be followed.
|
| Additional Infomation |
Phytic acid potassium is a research compound and not an approved drug. It has not undergone clinical trials for therapeutic use. It is being studied in preclinical research for potential applications in Alzheimer's disease (BACE1 inhibition), cancer (chelation and antioxidant properties), kidney stone prevention, and mineral metabolism. Phytic acid and its salts are generally recognized as safe (GRAS) for use as food additives and chelating agents in food processing. The compound is classified as an endogenous metabolite.
|
| Molecular Formula |
C6H16K2O24P6
|
|---|---|
| Molecular Weight |
736.21
|
| Exact Mass |
735.773
|
| CAS # |
129832-03-7
|
| PubChem CID |
22838972
|
| Appearance |
White to off-white solid powder
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
24
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
38
|
| Complexity |
976
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O=P(O)(O)O[C@@H]1[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O.[K].[K]
|
| InChi Key |
LFTTXUFEVNNTHA-OKBOCSEJSA-L
|
| InChi Code |
InChI=1S/C6H18O24P6.2K/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15;;/h1-6H,(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24);;/q;2*+1/p-2/t1-,2-,3?,4?,5-,6+;;/m0../s1
|
| Chemical Name |
dipotassium;[(2R,3S,5R,6R)-2,3,4,5,6-pentaphosphonooxycyclohexyl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (135.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3583 mL | 6.7915 mL | 13.5831 mL | |
| 5 mM | 0.2717 mL | 1.3583 mL | 2.7166 mL | |
| 10 mM | 0.1358 mL | 0.6792 mL | 1.3583 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
